317 related articles for article (PubMed ID: 37881499)
1. Role of glycolysis in inflammatory bowel disease and its associated colorectal cancer.
Xia Y; Zhang L; Ocansey DKW; Tu Q; Mao F; Sheng X
Front Endocrinol (Lausanne); 2023; 14():1242991. PubMed ID: 37881499
[TBL] [Abstract][Full Text] [Related]
2. Phytochemicals targeting glycolysis in colorectal cancer therapy: effects and mechanisms of action.
Zhan L; Su F; Li Q; Wen Y; Wei F; He Z; Chen X; Yin X; Wang J; Cai Y; Gong Y; Chen Y; Ma X; Zeng J
Front Pharmacol; 2023; 14():1257450. PubMed ID: 37693915
[TBL] [Abstract][Full Text] [Related]
3. The effects and mechanisms of isoliquiritigenin loaded nanoliposomes regulated AMPK/mTOR mediated glycolysis in colorectal cancer.
Wang G; Yu Y; Wang YZ; Yin PH; Xu K; Zhang H
Artif Cells Nanomed Biotechnol; 2020 Dec; 48(1):1231-1249. PubMed ID: 32985258
[TBL] [Abstract][Full Text] [Related]
4. SOCS3 in immune regulation of inflammatory bowel disease and inflammatory bowel disease-related cancer.
Li Y; de Haar C; Peppelenbosch MP; van der Woude CJ
Cytokine Growth Factor Rev; 2012 Jun; 23(3):127-38. PubMed ID: 22591635
[TBL] [Abstract][Full Text] [Related]
5. Dismicrobism in inflammatory bowel disease and colorectal cancer: changes in response of colocytes.
Tomasello G; Tralongo P; Damiani P; Sinagra E; Di Trapani B; Zeenny MN; Hussein IH; Jurjus A; Leone A
World J Gastroenterol; 2014 Dec; 20(48):18121-30. PubMed ID: 25561781
[TBL] [Abstract][Full Text] [Related]
6. Colorectal cancer in inflammatory bowel disease: the risk, pathogenesis, prevention and diagnosis.
Kim ER; Chang DK
World J Gastroenterol; 2014 Aug; 20(29):9872-81. PubMed ID: 25110418
[TBL] [Abstract][Full Text] [Related]
7. Novel Biomarkers for Inflammatory Bowel Disease and Colorectal Cancer: An Interplay between Metabolic Dysregulation and Excessive Inflammation.
Salla M; Guo J; Joshi H; Gordon M; Dooky H; Lai J; Capicio S; Armstrong H; Valcheva R; Dyck JRB; Thiesen A; Wine E; Dieleman LA; Baksh S
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36983040
[TBL] [Abstract][Full Text] [Related]
8. Exploring the glycolytic cross-talk genes between inflammatory bowel disease and colorectal cancer.
Ye C; Huang Y; Gao Y; Zhu S; Yuan J
Funct Integr Genomics; 2023 Jul; 23(3):230. PubMed ID: 37428395
[TBL] [Abstract][Full Text] [Related]
9. Implications of lymphatic alterations in the pathogenesis and treatment of inflammatory bowel disease.
Zhang L; Ocansey DKW; Liu L; Olovo CV; Zhang X; Qian H; Xu W; Mao F
Biomed Pharmacother; 2021 Aug; 140():111752. PubMed ID: 34044275
[TBL] [Abstract][Full Text] [Related]
10. Comparative analysis of single-cell transcriptome reveals heterogeneity and commonality in the immune microenvironment of colorectal cancer and inflammatory bowel disease.
Lv H; Mu Y; Zhang C; Zhao M; Jiang P; Xiao S; Sun H; Wu N; Sun D; Jin Y
Front Immunol; 2024; 15():1356075. PubMed ID: 38529274
[TBL] [Abstract][Full Text] [Related]
11. Metabolic evolutionary roots of the macrophage immune response in amoeba-bacteria interactions: The conserved role of hypoxia-induced Factor and AMP kinase.
Dzik J
Acta Biochim Pol; 2021 Aug; 68(3):457-476. PubMed ID: 34374500
[TBL] [Abstract][Full Text] [Related]
12. Histone demethylase JMJD2D activates HIF1 signaling pathway via multiple mechanisms to promote colorectal cancer glycolysis and progression.
Peng K; Zhuo M; Li M; Chen Q; Mo P; Yu C
Oncogene; 2020 Nov; 39(47):7076-7091. PubMed ID: 32989255
[TBL] [Abstract][Full Text] [Related]
13. Jiedu Sangen decoction inhibits chemoresistance to 5-fluorouracil of colorectal cancer cells by suppressing glycolysis via PI3K/AKT/HIF-1α signaling pathway.
Sun LT; Zhang LY; Shan FY; Shen MH; Ruan SM
Chin J Nat Med; 2021 Feb; 19(2):143-152. PubMed ID: 33641785
[TBL] [Abstract][Full Text] [Related]
14. Aspirin inhibits mTOR signaling, activates AMP-activated protein kinase, and induces autophagy in colorectal cancer cells.
Din FV; Valanciute A; Houde VP; Zibrova D; Green KA; Sakamoto K; Alessi DR; Dunlop MG
Gastroenterology; 2012 Jun; 142(7):1504-15.e3. PubMed ID: 22406476
[TBL] [Abstract][Full Text] [Related]
15. Overview of molecular pathways in inflammatory bowel disease associated with colorectal cancer development.
Azer SA
Eur J Gastroenterol Hepatol; 2013 Mar; 25(3):271-81. PubMed ID: 23169309
[TBL] [Abstract][Full Text] [Related]
16. Extracellular vesicles derived from gut microbiota in inflammatory bowel disease and colorectal cancer.
Alberti G; Mazzola M; Gagliardo C; Pitruzzella A; Fucarini A; Giammanco M; Tomasello G; Carini F
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2021 Sep; 165(3):233-240. PubMed ID: 34282804
[TBL] [Abstract][Full Text] [Related]
17. mTOR as a Potential Target for the Treatment of Microbial Infections, Inflammatory Bowel Diseases, and Colorectal Cancer.
Afzal O; Altamimi ASA; Mubeen B; Alzarea SI; Almalki WH; Al-Qahtani SD; Atiya EM; Al-Abbasi FA; Ali F; Ullah I; Nadeem MS; Kazmi I
Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293326
[TBL] [Abstract][Full Text] [Related]
18. Metagenome Analysis of Intestinal Bacteria in Healthy People, Patients With Inflammatory Bowel Disease and Colorectal Cancer.
Ma Y; Zhang Y; Xiang J; Xiang S; Zhao Y; Xiao M; Du F; Ji H; Kaboli PJ; Wu X; Li M; Wen Q; Shen J; Yang Z; Li J; Xiao Z
Front Cell Infect Microbiol; 2021; 11():599734. PubMed ID: 33738265
[TBL] [Abstract][Full Text] [Related]
19. Microbiota dysbiosis and barrier dysfunction in inflammatory bowel disease and colorectal cancers: exploring a common ground hypothesis.
Yu LC
J Biomed Sci; 2018 Nov; 25(1):79. PubMed ID: 30413188
[TBL] [Abstract][Full Text] [Related]
20. Mechanism of Bazhen decoction in the treatment of colorectal cancer based on network pharmacology, molecular docking, and experimental validation.
Lu S; Sun X; Zhou Z; Tang H; Xiao R; Lv Q; Wang B; Qu J; Yu J; Sun F; Deng Z; Tian Y; Li C; Yang Z; Yang P; Rao B
Front Immunol; 2023; 14():1235575. PubMed ID: 37799727
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
